

Nivolumab + ipilimumab CheckMate-9LA

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE



ADJUSTMENTS

Quality of life



Not qualified for an ESMO-MCBS credit



Serious and disabling adverse effects



Other adjustments



Nivolumab + ipilimumab CheckMate-9LA

SCORE

CURATIVE




Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE




Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Thoracic Malignancies
Therapeutic Indication: First line treatment of mNSCLC with no sensitising EGFR mutation or ALK translocation
Experimental Arm: Nivolumab + ipilimumab + 2 cycles of platinum-based ChT
Control Arm: Chemotherapy

